CytomX Therapeutics Inc (CTMX) — Cash Flow Quality Index
Latest as of March 2025:
-0.89x
CytomX Therapeutics Inc (CTMX) has a Cash Flow Quality Index of -0.89x as of March 2025. Operating cash flow of $-21.04 Million is below net income of $23.52 Million, suggesting accrual-heavy earnings not yet converted to cash. Explore CTMX cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.
Cash Flow Quality Index
-0.89x
Operating CF / Net Income
Operating Cash Flow
$-21.04 Million
USD
Net Income
$23.52 Million
USD
Data as of
Mar 2025
Most recent filing
CytomX Therapeutics Inc Cash Flow Quality Index (2024–2024)
Historical Cash Flow Quality Index for CytomX Therapeutics Inc across 1 annual periods. Values consistently above 1.0x indicate high-quality earnings. For the full cash flow conversion analysis, see CTMX cash flow conversion.
Annual Cash Flow Quality Index for CytomX Therapeutics Inc (2024–2024)
Year-by-year earnings quality comparison for CytomX Therapeutics Inc.
| Year | Quality Index | Operating CF (USD) | Net Income | YoY Change |
|---|---|---|---|---|
| 2024 | -2.71x | $-86.23 Million | $31.87 Million | — |
Cash Flow Quality Index = Operating Cash Flow / Net Income. Ratios above 1.0x indicate cash-backed earnings.